GATA3 Recombinant Rabbit Monoclonal Antibody (ZR358), RAbMono™, Zeta

Description

• This product is diluted and in a ready-to-use formulation
• A recommended positive control tissue for this product is breast or urothelial carcinoma, however positive controls are not limited to this tissue type
• The primary antibody is intended for laboratory professional use in the detection of the corresponding protein in formalin-fixed, paraffin-embedded tissue stained in manual qualitative immunohistochemistry (IHC) testing
• This antibody is intended to be used after the primary diagnosis of tumor has been made by conventional histopathology using non-immunological histochemical stains
• Antibody is used with formalin-fixed and paraffin-embedded sections
• Pretreatment of deparaffinized tissue with heat-induced epitope retrieval or enzymatic retrieval is recommended
• In general, immunohistochemical (IHC) staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody (link antibody), an enzyme complex and a chromogenic substrate with interposed washing steps
• The enzymatic activation of the chromogen results in a visible reaction product at the antigen site
• Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen
• A positive tissue control must be run with every staining procedure performed
• This tissue may contain both positive and negative staining cells or tissue components and serve as both the positive and negative control tissue
• External Positive control materials should be fresh autopsy/biopsy/surgical specimens fixed, processed and embedded as soon as possible in the same manner as the patient sample (s)
• Positive tissue controls are indicative of correctly prepared tissues and proper staining methods
• The tissues used for the external positive control materials should be selected from the patient specimens with well-characterized low levels of the positive target activity that gives weak positive staining
• The low level of positivity for external positive controls is designed to ensure detection of subtle changes in the primary antibody sensitivity from instability or problems with the staining methodology
• A tissue with weak positive staining is more suitable for optimal quality control and for detecting minor levels of reagent degradation
• Internal or external negative control tissue may be used depending on the guidelines and policies that govern the organization to which the end user belongs to
• The variety of cell types present in many tissue sections offers internal negative control sites, but this should be verified by the user
• The components that do not stain should demonstrate the absence of specific staining, and provide an indication of non-specific background staining
• If specific staining occurs in the negative tissue control sites, results with the patient specimens must be considered invalid.